Magdalena Kovacsovics-Bankowski, Johanna M Sweere, Connor P Healy, Natalia Sigal, Li-Chun Cheng, William D Chronister, Shane A Evans, John Marsiglio, Berit Gibson, Umang Swami, Alyssa Erickson-Wayman, Jordan P McPherson, Yoko S Derose, Annaleah Larson Eliason, Carlos O Medina, Ramji Srinivasan, Matthew H Spitzer, Ngan Nguyen, John Hyngstrom, Siwen Hu-Lieskovan
BACKGROUND: Immune-related adverse events (irAEs) are major barriers of clinical management and further development of immune checkpoint inhibitors (ICIs) for cancer therapy. Therefore, biomarkers associated with the onset of severe irAEs are needed. In this study, we aimed to identify immune features detectable in peripheral blood and associated with the development of severe irAEs that required clinical intervention. METHODS: We used a 43-marker mass cytometry panel to characterize peripheral blood mononuclear cells from 28 unique patients with melanoma across 29 lines of ICI therapy before treatment (baseline), before the onset of irAEs (pre-irAE) and at the peak of irAEs (irAE-max)...
January 17, 2024: Journal for Immunotherapy of Cancer